Navigation Links
The Lancet Publishes Data from Protege, MacroGenics' Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
Date:6/28/2011

clude patients for whom treatment is begun less than or equal to 6 weeks after diagnosis and in children 8 -11 years old.  In the coming months, MacroGenics will be exploring possible pathways forward for continued development of teplizumab."

About Type 1 Diabetes

Type 1 diabetes is an autoimmune disease in which the body's immune system attacks and destroys the insulin-producing beta cells of the pancreas. Insulin is a hormone that is needed to convert sugar (glucose), starches and other food into energy needed for daily life. People with type 1 diabetes must take multiple injections of insulin daily or continually infuse insulin through a pump to manage their blood glucose levels.

Type 1 diabetes, previously known as juvenile diabetes, usually strikes in childhood, adolescence, or young adulthood, but lasts for a lifetime. Of the nearly 24 million Americans who have diabetes, as many as 3 million may have type 1.

About Teplizumab

Teplizumab, also called MGA031 and hOKT3-gamma1 (Ala-Ala), is a humanized, anti-CD3 monoclonal antibody. Teplizumab binds to an epitope of the CD3-epsilon chain expressed on mature T lymphocytes and, by doing so, may modulate the pathological immunologic responses underlying multiple autoimmune diseases. Specifically, teplizumab may inhibit unwanted effector T cells and enhance beneficial regulatory T cell functions, thus promoting immune tolerance.  MacroGenics retains full worldwide rights to teplizumab.

About MacroGenics, Inc.    

MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for autoimmune disorders, cancer and infectious diseases. The company has built a fully-integrated set of capabilities in antibody-based product development which supports its innovative pipeline of clinical stage product candidates. MacroGenics' proprietary research is b
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumos HydroCoil® Embolic System for Treatment of Cerebral Aneurysms
2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
3. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
4. CHAMPION Study Published in The Lancet
5. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
6. Phase III Data Showing Improved Survival With Jevtana® (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
7. Data Published in The Lancet Compare Dabigatran Etexilate to Dose-Adjusted Warfarin Across RE-LY® Trial Centers
8. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
9. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
10. The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
11. Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... WASHINGTON , Jan. 23, 2015  A new analysis ... Part D 2015 enrollment data shows that 81 percent ... convenient access and extra discounts at certain pharmacies. The ... "Preferred pharmacy plans are now the foundation of ...
(Date:1/23/2015)... Jan. 23, 2015  MedScope ( www.medscope.org ), the leading ... a 2015 Connected World magazine Connected World ... (mPERS), that can be used anywhere, anytime. The nomination ... In nominating MedScope, Landon Garner , ...
(Date:1/23/2015)... , Jan. 23, 2015  Immune Therapeutics, Inc. today announced the ... the compounding, packaging and distributing of its naltrexone tablets.  The ... United States . KRS Global is ... tablets in various strengths for individual patients in response to ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4
... N.J. , Feb. 5 Strativa Pharmaceuticals announced ... a complete response letter regarding the new drug application (NDA) ... nausea and vomiting associated with highly- and moderately-emetogenic chemotherapy, radiotherapy ... foreign travel in India , the FDA has been ...
... , BOSTON , Feb 5 Solos ... Company has signed an agreement with Expert Resource (ER) to ... quality management system (QMS) initiative. Expert Resource will provide comprehensive ... a quality management system that meets the requirements of the ...
Cached Medicine Technology:Strativa Pharmaceuticals Provides An Update On Zuplenz(R) (Ondansetron) Oral Soluble Film 2Strativa Pharmaceuticals Provides An Update On Zuplenz(R) (Ondansetron) Oral Soluble Film 3Solos Endoscopy, Inc. Retains Expert Resource to Meet Requirements for ISO 13485 Quality Management System Initiative 2
(Date:1/22/2015)... is a seasoned and trusted leader who consistently delivers trendy ... have it lead the wedding dress industry into the future. ... for the global market. , “The CEO of VogueQueen is ... on continuing the goal of operational excellence and giving back ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne ... highest annual revenues in the past three years. Today, the ... dresses. , According to the sales manager of the company, ... them in 2015. This point can be reflected on the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 As interest in ... health care gains momentum worldwide, Rev. Eric J. Hall ... Chaplaincy Network (HCCN), will be the keynote speaker on ... in Israel’s public health system. , The conference, “Hope and ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... day boosts protection for nonsmokers, study finds , , MONDAY, ... lower the risk for stroke among women, with more ... suggest. , The finding stems from the tracking of ... thousands of American women across nearly a quarter century. ...
... high-demand fieldsMINNEAPOLIS, Feb. 16 Walden University , ... offering three new degree programs designed to meet increasing ... instructional design and technology, and management leadership with the ... in Instructional Design and Technology, and M.S. in Leadership ...
... Inc. (WHI) today announced that the International Finance Corporation ... $15 million project financing facility. The facility is in ... than 600 communities in India fund the purchase of ... capacity to serve more than three million people."In response ...
... FARMS, Mich., Feb. 16 my ... that over one million e-Prescriptions have been sent from ... 1HIE has worked with physicians to help them actively ... (SM) Physician Web Portal. Working with its member physicians ...
... times more likely to develop malignancies after radiation treatments ... ironic testament to the success of childhood cancer treatments, ... with radiation for Hodgkin,s disease were almost 40 times ... , "We can cure most patients now who have ...
... Fewer caloriesFORT WORTH, Texas, Feb. 16 ... industry by becoming the first Mexican brand ... Calorie products. Building on Marinela,s commitment to ... line offers the perfect portions while maintaining ...
Cached Medicine News:Health News:Coffee Drinking Lowers Women's Stroke Risk 2Health News:Coffee Drinking Lowers Women's Stroke Risk 3Health News:Coffee Drinking Lowers Women's Stroke Risk 4Health News:Walden University Offers a New M.S. in Leadership Degree and New Bachelor's Degrees in Instructional Design and Technology and in Nursing 2Health News:Walden University Offers a New M.S. in Leadership Degree and New Bachelor's Degrees in Instructional Design and Technology and in Nursing 3Health News:WaterHealth International Announces $15 Million Financing by IFC 2Health News:my1HIE Reaches 1 Million e-Prescriptions 2Health News:Hodgkin's Survivors Prone to Breast Cancer Later 2Health News:Hodgkin's Survivors Prone to Breast Cancer Later 3Health News:Marinela USA(R) Launches 100 Calorie Product Line 2
The compact, simple-to-use ECG for medical professionals....
The Wills Eye Manual, Fourth Edition has been updated to include the newest drugs, procedures, and treatment protocols. Clinicians will have instant access to current information on diagnosis and tre...
... Cochrane Reviews enable all those involved ... date with the very latest evidence in ... which becomes harder each year as the ... this problem by delivering the best single ...
The ideal on-the-spot reference for residents and practitioners seeking fast facts on fracture management....
Medicine Products: